Friday, April 25, 2014
08:30-10:00 |
IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP): SOME ASPECTS OF TREATMENT |
| Capsule | During the past three decades intravenous gammaglobulin therapy has evoked clinical and laboratory research on the mechanisms of action in disorders with immune pathogenesis. It was recognized that IVIG modulates the disturbed immune response in multiple, synergistic ways between the different components of the immune system. Following this observation anti-D immunonoglobulin, anti-CD monoclonal antibodies and cyclosporin A – probably also the thrombopoietin receptor antagonists – were recognized as biologic immunomodulators. The various mechanisms of action of immunomodulators will be discussed |
| Chairperson | P. Imbach, Switzerland |
| 08:30 | Immunomodulation in ITP P. Imbach, Switzerland |
| 09:00 |
Debate: Intervention in childhood ITP: Yes or no?Yes: A. Schifferli, Switzerland .No: P. Bolton-Maggs, UK Discussion |
10:20-11:50 |
IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP): TREATMENT MODALITIES |
| Chairpersons | P. Imbach, Switzerland T. Kuehne, Switzerland |
| 10:20 | Update on the intercontinental cooperative ITP study group (ICIS) and on the pediatric registry on chronic ITP (PARC ITP) T. Kuehne, Switzerland |
| 10:50 | Duration and morbidity of chronic immune thrombocytopenic purpura in children: Results of the Nordic cohort S. Rosthoej, Denmark |
| 11:20 | Children with acute ITP should be treated only according to bleeding score S. Revel-Vilk, Israel |
12:10-13:40 |
APLA, ANTI PHOSPHOLIPID SYNDROME (APS): UNIQUE PRESENTATION OR A DIFFERENT ENTITY |
| Capsule |
APLA and APS in children: Adult criteria for diagnosis of antiphospholipid syndrome (APS) are applied for pediatric cases as well, although recurrent pregnancy loss is not applicable for children. As perinatal arterial stroke may present with persistent antiphospholipid antibodies (and thus be defined as APS), either unique APS presentation or a different entity in infants should be considered, and certainly affects future management.
|
| Chairpersons: | N. Toplak, Slovenia V. Pengo, Italy |
| 12:10 | Diagnostic criteria for APS V. Pengo, Italy |
| 12:40 | Pediatric APS and the international pediatric-APS registry N. Toplak, Slovenia |
| 13:10 | Lab diagnosis of APLA G. Sarig, Israel |
14:30-16:00 |
HEMOSTASIS AND ADOLESCENTS |
| Capsule | Estrogen therapy increases the risk of thrombosis. The increased risk is related to type and dose of both estrogen and combined progestagen and mode of delivery. Many questions arise, like: Which kind of oral contraceptive should we prescribe? Is thrombophilia testing in adolescents females required? And more |
| Chairpersons: | B. Brenner, Israel J. Rabinovici, Israel |
| 14:30 | Oral contraceptives: Which kind should we prescribe? J. Rabinovici, Israel |
| 15:00 | Is thrombophilia testing in adolescents useful? B. Brenner, Israel |
| 15:30 | Menorrhagia in adolescents S. Revel-Vilk, Israel |
Saturday, April 26, 2014
08:30-10:00 |
INHERITED BONE MARROW FAILURE |
| Capsule |
Inherited Bone Marrow Failure (IBMF) – including Fanconi anemia, Diamond Blackfan Anemia, severe congenital neutropenia, Shwachman-Diamond syndrome, dyskeratosis congenital, congenital amegakaryocytic thrombocytopenia and thrombocytopenia with absent radii - is a relatively rare entity in pediatrics, however, early and prompt diagnosis are crucial for optimal therapy and genetic counseling. Bicytopenia and pancytopenia may be encountered quite often in the first years of life. In this session we will highlight the specific characteristics of IBMF (physical examination, laboratory work-up and more) that will direct us to the diagnosis of IBMF.
|
| Chairperson | H. Tamary, Israel |
| 08:30 | Overview: Inherited Bone Marrow Failure H. Tamary, Israel |
| 09:00 | Approach to Neutropeia in children K. Welte, Germany |
| 09:30 | The neonatologist and the diagnosis of inherited bone marrow failure syndromes C. Dufour, Italy |
10:20-11:50 |
ANEMIA |
| Capsule | Anemia of acute infection – frequently seen, however a big enigma – will be characterized in the session. Clinical studies disclose frequency and severity of this phenomenon. An animal model (mouse) proposes the pathophysiology |
| Chairperson | A. Ballin, Israel |
| 10:20 | Iron deficiency anemia: Still a problem A. Ballin. Israel |
| 10:50 | Autoimmune Hemolytic Anemia H. Tamary, Israel |
| 11:20 | Anemia of acute infection A. Ballin, Israel |
12:10-13:40 |
NEONATAL INTRAVENTRICULAR HEMORRHAGE (IVH): IS THIS A BLEEDING DISORDER? |
| Capsule |
Neonatal IVH is a devastating complication of prematurity. The immature fetal hemostatic systems render those infants, born extremely premature, highly susceptible for bleeding. Nonetheless, as coagulation inhibition is seriously impaired, the risk of thrombosis following venous congestion is also increased
|
| Chairpersons | G. Kenet, Israel L. Ramenghi, Italy |
| 12:10 |
Debate:Is IVH of prematurity a bleeding disorder? G. Kenet, IsraelIs IVH a result of thrombophilic risk factors? L. Ramenghi, Italy |
|
Panelists:
G. Kenet, Israel
L. Ramenghi, Italy
Panel discussion on the following topics:
|
14:30-16:00 |
PEDIATRIC VENOUS THROMBOEMBOLISM (VTE) |
| Chairperson | U. Nowak-Göttl, Germany |
| 14:30 | Epidemiology of VTE in children U. Nowak-Göttl, Germany |
| 15:00 |
Debate: Should we screen kids with Central Vein Line thrombosis for thrombophilia?
Yes: A.C. Molinari, ItalyNo: H. Van Ommen, Netherlands Discussion |
16:30-18:00 |
NEONATAL THROMBOSIS AND CONGENITAL BLEEDING DISORDERS |
| Capsule |
Neonatal thrombosis is far more prevalent as compared to late childhood, yet chances of recurrent thrombosis in infants are slim. In the following session some common aspects of diagnosis and treatment of typical thromboembolic events in infants will be discussed. The lecturers will address pathophysiology, diagnosis and therapy of renal vein thrombosis, portal vein thrombosis and cerebral sinus vein thrombosis in neonates
|
| Chairpersons | M. Van Den Berg, Netherlands A.K. Chan, Canada |
| 16:30 | Hemostasis in neonates: Developmental aspects G. Kenet, Israel |
| 17:00 | Abdominal thrombosis of neonates (RVT, PVT) A.K. Chan, Canada |
| 17:30 |
Inhibitor epidemiology and risk factors-lessons learned from international hemophilia multicenter studies |
Sunday, April 27, 2014
08:30-10:00 |
CONTROVERSIES IN CHILDREN WITH IMPAIRED BETA-CELL FUNCTION: TOO MUCH OR TOO LITTLE INSULIN |
| Chairperson | K. Hussain, UK |
| 08:30 | Neonatal diabetes: To treat with insulin or sulphonylureas? J. Lebl, Czech Republic |
| 09:00 | Controversies in children with hyperinsulinism K. Hussain, UK |
| 09:30 |
Genetic investigation in children with diabetes. Who investigates and who doesn’t?
S. Pruhova, Czech Republic |
10:30-11:30 |
PEDIATRIC STROKE |
| Capsule |
Stroke in children is a rare but significant cause of death and long-term disability. With increased understanding, improved guidelines, and emerging treatment options for children's stroke, increased awareness about this disease is necessary for prompt identification and treatment in this population |
| Chairperson | U. Nowak-Göttl, Germany |
| 10:30 | Old and new risk factors for pediatric stroke U. Nowak-Göttl, Germany |
| 11:00 | Genome wide association studies in pediatric stroke M. Stoll, Germany |
